Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.82 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | MTOR | P42345 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | HTR2C | P28335 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norfluoxetine SCHEMBL686500 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Norfluoxetine SCHEMBL3750512 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Norfluoxetine SCHEMBL140929 | 0.98 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Seproxetine SCHEMBL120303 | 0.98 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Norfluoxetine SCHEMBL7306073 | 0.93 | SLC6A4 (0.87) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17267513 | 0.90 | SLC7A5 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17267476 | 0.90 | SLC7A5 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17267474 | 0.90 | SLC7A5 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL17267515 | 0.89 | SLC7A5 (1.00) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL2738930 | 0.88 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 451 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514883-B2 | Compositions and methods for modulating lipid and steroid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-06 | — | — | US | claimed |
| US-20250195505-A1 | USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN | BIOBINA LLC | 2025-06-19 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250161296-A1 | USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN | BIOBINA LLC | 2025-05-22 | — | — | US | claimed |
| US-12303503-B1 | Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain | BIOBINA LLC (US) | 2025-05-20 | — | — | US | claimed |
| EP-4536231-A1 | TREATMENT OF ANTIDEPRESSANT RESISTANT SUBJECTS | Actinogen Medical Limited (AU) | 2025-04-16 | — | — | EP | claimed |
| EP-3294337-B1 | TREATMENT OF DEBILITATING FATIGUE BY COMBINED USE OF 3(S)-3-[3-(METHYLSULFONYL)PHENYL]-1- PROPYLPIPERIDINE AND AN ANTI-DEPRESSIVE AGENT | ARVID CARLSSON RES AB (SE) | 2024-12-18 | — | — | EP | claimed |
| WO-2023235937-A1 | TREATMENT OF ANTIDEPRESSANT RESISTANT SUBJECTS | Actinogen Medical Limited (AU) | 2023-12-14 | — | — | WO | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| US-20230313301-A1 | METHODS OF IDENTIFYING AUTISM SPECTRUM DISORDER | WASHINGTON STATE UNIVERSITY | 2023-10-05 | — | — | US | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007006132-A1 | AN EFFICIENT METHOD FOR PREPARING 3-ARYLOXY-3- ARYLPROPYLAMINES AND THEIR OPTICAL STEREOISOMERS | APOTEX PHARMACHEM INC. (CA) | 2007-01-18 | — | — | WO | claimed |
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | APOTEX PHARMACHEM INC. | 2007-01-11 | — | — | US | claimed |
| EP-1687000-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | claimed |
| EP-1644000-A1 | COMPOSITIONS CONTAINING A SEROTONIN SELECTIVE REUPTAKE INHIBITOR AND A 5-HT2A RECEPTOR ANTAGONIST | Pfizer Products Inc. (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005048999-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| US-20050070577-A1 | Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist | PFIZER INC. | 2005-03-31 | — | — | US | claimed |
| WO-2005002578-A1 | COMPOSITIONS CONTAINING A SEROTONIN SELECTIVE REUPTAKE INHIBITOR AND A 5-HT2A RECEPTOR ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2005-01-13 | — | — | WO | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| WO-1992000103-A1 | PHARMACEUTICAL PREPARATIONS | BEECHAM GROUP PLC (GB) | 1992-01-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | SLC6A4, HTR3A, TPH2 | SLC6A4 1/4885SLC6A2 13/4885SLC6A3 12/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | SLC6A4 25/4885SLC6A2 44/4885SLC6A3 30/4885 |
| US-20050070577-A1 | Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist | HTR2A, HTR5A, HTR2C | SLC6A4 12/4885SLC6A2 19/4885SLC6A3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.